Nitschmann Caroline, May Taymaa, Mirkovic Jelena, Feldman Sarah
1 Department of Obstetrics and Gynecology, Division of Gynecologic Surgery , Mayo Clinic, Rochester, Minnesota.
2 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Princess Margaret Cancer Center , Toronto, Canada .
J Womens Health (Larchmt). 2016 Aug;25(8):826-31. doi: 10.1089/jwh.2015.5394. Epub 2016 Feb 9.
Updated guidelines for the screening and management of cervical cancer in the United States recommend starting Papanicolaou (Pap) testing at age 21 and screening less frequently with less aggressive management for abnormalities. We sought to examine updated Pap test screening guidelines and how they may affect the detection of invasive cervical cancer, especially among women <30 years of age.
Patients diagnosed at Brigham and Women's Hospital with invasive cervical cancer between 2002 and 2012 were retrospectively identified. Prior screening history was obtained and patients were divided into two groups based on age <30 years or age ≥30 years. The two groups were then compared with respect to demographics, pathological findings, and time to diagnosis.
A total of 288 patients with invasive cervical carcinoma were identified. Among these patients, 109 had adequate information on prior screening history. Invasive adenocarcinoma (IAC) was diagnosed in 37 (33.94%) patients, whereas 64 (58.72%) patients were diagnosed with invasive squamous cell carcinoma (ISCC). The remaining eight patients were diagnosed with other types of cancers of the cervix. A total of 13 patients were younger than 30 while 96 patients were 30 or older. The mean time from normal Pap to diagnosis of IAC was 15 months in patients younger than 30 years of age compared to 56 months in patients aged 30 and older (p < 0.001). The mean time from normal Pap to diagnosis of ISCC was 38 months in patients younger than 30 years of age and 82 months in patients aged 30 and older (p = 0.018).
In this small retrospective study, updated Pap test screening guidelines would not have missed invasive cancer on average among screened women age 30 and older. However, young patients aged 21-29 years may be at increased risk of developing IAC of the cervix between the recommended screening intervals.
美国宫颈癌筛查与管理的更新指南建议,21岁开始进行巴氏涂片检查(Pap检测),对异常情况采用侵袭性较小的管理方式,筛查频率降低。我们试图研究更新后的Pap检测筛查指南及其对浸润性宫颈癌检测的影响,尤其是在30岁以下女性中。
回顾性确定2002年至2012年在布莱根妇女医院诊断为浸润性宫颈癌的患者。获取既往筛查史,并根据年龄<30岁或年龄≥30岁将患者分为两组。然后比较两组在人口统计学、病理结果和诊断时间方面的情况。
共确定288例浸润性宫颈癌患者。其中,109例患者有足够的既往筛查史信息。37例(33.94%)患者诊断为浸润性腺癌(IAC),64例(58.72%)患者诊断为浸润性鳞状细胞癌(ISCC)。其余8例患者诊断为其他类型的宫颈癌。共有13例患者年龄小于30岁,96例患者年龄为30岁及以上。年龄小于30岁的患者从正常Pap检测到诊断IAC的平均时间为15个月,而年龄30岁及以上的患者为56个月(p<0.001)。年龄小于30岁的患者从正常Pap检测到诊断ISCC的平均时间为38个月,年龄30岁及以上的患者为82个月(p=0.018)。
在这项小型回顾性研究中,更新后的Pap检测筛查指南平均不会漏诊30岁及以上筛查女性中的浸润性癌症。然而,21 - 29岁的年轻患者在推荐的筛查间隔期间发生宫颈IAC的风险可能会增加。